Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Burkitt Lymphoma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Mantle-Cell 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Biphenotypic, Acute 2Down Syndrome 2Blast Crisis 2Renal Pelvis and Ureter Urothelial Carcinoma 1Osteosarcoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1Anemia, Refractory, with Excess of Blasts 1

Interventions

X-Rays 5Phantoms, Imaging 5Magnetic Resonance Spectroscopy 5Nuclear Medicine Department, Hospital 4Cyclophosphamide 4fludarabine 3Specimen Handling 3Gemcitabine 3Doxorubicin 3Biopsy 3ulixertinib 2tipifarnib 2selpercatinib 2olaparib 2larotrectinib 2ivosidenib 2ensartinib 2cabozantinib 2Methotrexate 2Mesna 2Ifosfamide 2Eflornithine 2Cisplatin 2tazemetostat 1talazoparib 1selinexor 1pazopanib 1palbociclib 1mifamurtide 1merphos 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Osteosarcoma × merphos × 30 days × Clear all
NCT05691478 2026-06-03

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

National Cancer Institute (NCI)

Phase 2/3 Recruiting
1,122 enrolled
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡